Detalhe da pesquisa
1.
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial.
Lancet Oncol
; 24(3): 213-227, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36796394